ESPR
Esperion Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Esperion Therapeutics has 1 disclosed supplier and 6 disclosed customers in SEC filings.
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Expected move
No implied move.
−11.18%
vs ±15.3% implied · ×0.73
shaded = implied · ▲▼ = realized
SentenceWe announced collaboration agreements for the commercialization of bempedoic acid and the bempedoic acid / ezetimibe combination tablet with DSE in 2019, with Otsuka in 2020, and with Daiichi Sankyo Co. Ltd, or DS, in 2021.
ESPR 10-Kaccession 0001628280-26-016522
SentenceCollaboration revenue in the year ended December 31, 2024 was primarily related to the Settlement Agreement with DSE, a milestone from Otsuka upon first Japanese New Drug Application, or JNDA, submission in the Otsuka Territory, sales of bulk tablets under supply agreements and royalty revenue received from collaboration partners.
ESPR 10-Kaccession 0001628280-26-016522
SentenceCollaboration revenue in the year ended December 31, 2025 was primarily related to milestone payments from Otsuka related to NEXLETOL approval in the Otsuka Territory, the first NHI Price Listing for NEXLETOL in the Otsuka Territory, and the achievement of the primary major adverse cardiovascular events, or MACE, endpoint in the CLEAR Outcomes study and inclusion of the CV risk reduction indication in the U.S. label, as well as an upfront milestone payment from HLS Therapeutics Inc., or HLS, sales of bulk tablets under supply agreements and royalty revenue received from collaboration partners.
ESPR 10-Kaccession 0001628280-26-016522
SentenceOn December 12, 2024, we entered into a license and collaboration agreement with Neopharm. Under the terms of the agreement, we granted Neopharm exclusive commercialization rights to NEXLETOL and NEXLIZET in Israel, Gaza, and West Bank.
ESPR 10-Kaccession 0001628280-26-016522
SentenceOtsuka Pharmaceutical Co., Ltd., or Otsuka, our Japanese collaborator, received approval from the Japanese Ministry of Health, Labour and Welfare to market NEXLETOL as a treatment for hypercholesterolemia and familial hypercholesterolemia in September 2025, with National Health Insurance, or NHI, pricing received in the fourth quarter of 2025.
ESPR 10-Kaccession 0001628280-26-016522
SentenceOn February 26, 2025, we entered into a license and distribution agreement with Seqirus Pty Ltd, or CSL Seqirus, for the rights to commercialize NEXLETOL and NEXLIZET in Australia and New Zealand.
ESPR 10-Kaccession 0001628280-26-016522
Linked news
Esperion Therapeutics, Inc.
3.19
0.00 · −0.16%
post 3.20 +0.47%